[go: up one dir, main page]

WO1991012272A1 - Facteur proteique - Google Patents

Facteur proteique Download PDF

Info

Publication number
WO1991012272A1
WO1991012272A1 PCT/GB1991/000245 GB9100245W WO9112272A1 WO 1991012272 A1 WO1991012272 A1 WO 1991012272A1 GB 9100245 W GB9100245 W GB 9100245W WO 9112272 A1 WO9112272 A1 WO 9112272A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
antibody
human
nucleic acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/000245
Other languages
English (en)
Inventor
Michael Stoker
Ermanno Gherardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Horizons Ltd
Original Assignee
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Cancer Research Technology Ltd filed Critical Imperial Cancer Research Technology Ltd
Publication of WO1991012272A1 publication Critical patent/WO1991012272A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to proteins, polypeptides, nucleic acid fragments, antibodies and related products and their use in diagnosis and therapy.
  • Scatter factor is a fibroblast-derived protein which causes separation of contiguous epithelial cells and increased local mobility of unanchored cells [Stoker and Perry an, J.Cell Sci.. 72:209-223 (1985)]. This activity may be of use in enhancing repair of wounds, such as severe burns and chronic skin ulcers, and inhibition of the activity of scatter factor or related proteins, for example using neutralising antibodies, may be of use in inhibiting metastasis of tumours.
  • the present inventors have elucidated the N-terminal seguence of one chain of scatter factor, thereby enabling the construction of nucleotide probes to identify RNA and DNA sequences encoding scatter factor, the isolation and cloning of mRNA and genomic or complementary DNA and thus large scale production by expression in host cells of scatter factor. This may itself be used therapeutically and diagnostically and it may also be used to generate diagnostically and therapeutically useful antibodies.
  • Polypeptides and proteins of the invention incorporating a part or the whole of the sequence of formula (I) below are useful in generating antibodies for therapeutic and diagnostic uses and can be used as immunogens for treatment or prophylaxis of cancer. They may also be used, provided that they contain the functional portion(s) of scatter factor, to initiate or expedite wound healing.
  • a polypeptide or protein comprising at least five contiguous amino acids in a sequence corresponding to formula (I)
  • X 1 is any naturally occurring L-amino acid residue and X 2 is any amino acid residue, but is preferably a L- leucine residue (L) .
  • L L- leucine residue
  • polypeptides and proteins of the invention comprise at least 6 contiguous amino acid residues in a seguence corresponding to formula (I) .
  • polypeptides of the invention are 6 or more amino acid residues in length they must contain a portion of at least 5 amino acid residues identical to formula (I) but the remainder of the sequence may be unrelated to formula (I) , related to but not identical (ie. homologous) or identical to formula (I) .
  • Sequences differing from formula (I) may vary by way of substitution, deletion and/or insertion of one or more amine acid residues at one or more loci.
  • polypeptides are longer than 20 amino acid residues and comprise a sequence of 20 amino acid residues homologous with or more preferably, identical to the sequence of formula (I) .
  • Proteins according to the invention may comprise one polypeptide chain or more than one polypeptide chain linked covalently by disulphide bonds or otherwise or by non-covalent interactions but the invention does not extend to naturally occurring scatter factor or the 57 kDa and 30 kDa subunits thereof as produced by reductive cleavage of naturally occurring scatter factor.
  • polypeptides of the invention may include other parts of scatter factor, and/or carrier proteins such as keyhole limpet haemocyanin, albumen or thyroglobulin or polio virus capsid protein.
  • carrier proteins such as keyhole limpet haemocyanin, albumen or thyroglobulin or polio virus capsid protein.
  • polypeptides of the invention may additionally bear linkage sugars, such as N-acetyl galactosamine on serine and/or threonine residues, or oligosaccharide moieties linked to the polypeptide via linkage sugars.
  • linkage sugars such as N-acetyl galactosamine on serine and/or threonine residues, or oligosaccharide moieties linked to the polypeptide via linkage sugars.
  • Polypeptides and proteins according to the invention may be produced by modification of naturally occurring scatter factor, by de novo synthesis or by expression of appropriate nucleic acid coding sequences or a combination of such techniques which are described below.
  • Polypeptides and proteins according to the invention may be produced by de novo synthesis by conventional techniques. Scatter factor may be obtained from cell culture [see Gherardi et al, Proc.Natl.Acad.Sci. , j$ : 5844- 5848 (1989)] and modified by conventional techniques [see Gherardi ibid] .
  • the polypeptides and proteins of the invention are produced by expression of DNA encoding the polypeptide or protein, in a suitable prokaryotic or eukaryotic expression system (see Molecular Cloning: A
  • the invention further provides a process for producing a polypeptide or protein as hereinbefore defined by linking amino acid residues or oligopeptides in an appropriate sequence, or by expressing the polypeptide in a suitable expression system as hereinbefore described and recovering the polypeptide from the cell debris or culture medium.
  • the polypeptides and proteins of the invention may be used in therapy and diagnosis or to generate antibodies for use in therapy or diagnosis.
  • the polypeptides or proteins will be administered in effective, non-toxic amounts in order to promote invasion of wounds by epithelial cells so as to encourage wound healing.
  • the polypeptide or protein is administered as a pharmaceutical formulation comprising a pharmaceutically acceptable carrier or diluent.
  • Preferred carriers and diluents will be selected according to the route of administration.
  • the carriers and diluents may be liquids or solids and the polypeptide or protein may be formulated as a solution, suspension or mixture.
  • the carrier or diluent will generally be sterile, pyrogen-free liguid, preferably water for injection and the polypeptide or protein will be present in solution or suspension.
  • the carrier or diluent may optionally include accessory ingredients such as preservatives, anti-oxidants, flavouring agents, colouring agents, suspending agents such as detergents or emulgents, buffers and isotonic agents.
  • the carrier or diluent will be a suitable solvent, cream or lotion base and the formulation may further comprise optional accessory ingredients such as preservatives, antioxidants , suspending agents, including detergents and emulgents, and buffers.
  • Amounts to be administered will be selected according to the age, weight or body area, sex and state of health of the patient and the size of the wound(s) , ulcer(s) or area to be treated. As a guide a single dose for a normal human would generally be in the range of from 1 to 1000 ng, for instance 100 to 300 ng.
  • polypeptides and proteins may be used in conventional diagnostic tests or assays, for instance to detect antibodies against scatter factor in samples of a patient's body fluid or to competitively inhibit binding of scatter factor to anti-scatter factor antibodies in competitive tests or assays for scatter factor.
  • the polypeptides and proteins of the invention may be labelled, for instance with radionuclides, fluorescent labels or enzyme labels or bound to particles or solid supports. Such labelling is achieved by conventional methods well-known in the art. Nucleic acid fragments
  • the present invention further provides nucleic acid fragments which encode polypeptides and proteins as hereinbefore defined or which are related hereto.
  • Single stranded fragments may be coding strands i.e. template-strand DNA or message strand RNA) or complementary strands (i.e. non-template strand DNA or anti-sense RNA) .
  • Coding strands will contain an open reading frame comprising 15 contiguous nucleotides in a sequence of codons encoding 5 contiguous amino acid residues in a sequence corresponding to formula (I) .
  • Complementary strands will have a sequence of 15 contiguous nucleotides in a sequence exactly complementary to a coding strand.
  • Double stranded nucleic acid fragments may be RNA or, preferably, DNA and comprise a coding strand and an exactly complementary strand, the coding strand comprising 15 contiguous nucleotides in an open reading frame sequence of codons encoding 5 contiguous amino acid residues in a sequence corresponding to formula (I) .
  • a second class of nucleic acid fragments according to the invention are fragments hybridisable with fragments of the first class.
  • Fragments of the second class may be single or double stranded DNA or RNA but need not encode an amino acid sequence nor be complementary to a coding sequence as it is not essential that they have an exactly complementary sequence for hybridisation to occur.
  • such fragments must be hybridisable to fragments of the first class at least under low stringency conditions and preferably under high stringency conditions.
  • Such fragments differ from fragments of the first class by substitution, deletion or insertion at one or more loci.
  • class two fragments have at least 75% homology, over the relevant region, with class one fragments, more preferably at least 90% and most preferably 95% or more homology.
  • the class two fragment will differ from the class one fragment at only one or two bases. Larger fragments also preferably only differ at one or two bases from class one fragments. Differences may be substitutions, deletions or insertions or any combination thereof.
  • Low stringency as defined above corresponds with about 75% homology.
  • High stringency as defined above corresponds with about 95% homology.
  • Fragments of the invention are preferably at least 17, more preferably at least 18 nucleotides or nucleotide base pairs in length, more preferably at least 21 bases or base pairs and yet more preferably at least 30 nucleotide bases or base pairs in length.
  • Fragments longer than 15 nucleotide bases or base pairs must contain coding, complementary or hybridisable sequences of at least 15 nucleotide bases or base pairs in length as described above. The remainder of such fragments may be unrelated to the sequence of formula (I) , may encode, or be complementary to; a sequence encoding a polypeptide related to or identical to that of formula (I) or may hybridise to a sequence which encodes or is complementary to a sequence encoding; a polypeptide related to or identical to that of formula (I) .
  • the nucleic acid fragments of the invention may be obtained from natural sources such as mRNA or genomic DNA of cells actively expressing or capable of expressing scatter factor (in which case they must be in pure form or in a form substantially free from mRNA or DNA fragments not encoding scatter factor) .
  • the fragments may be produced by mutagenesis of such naturally occurring mRNA or DNA, by transcription of genomic DNA or reverse transcription from naturally occurring mRNA or transcription of genomic DNA, by partial or total de novo synthesis or by a combination of such techniques as will be described below.
  • Nucleic acid fragments according to the invention may be produced de novo by conventional techniques [see Maniatis] or recovered from cells, such as foetal fibroblasts, or by conventional methods and may be cloned in suitable cloning systems [Maniatis] such as described below.
  • Fragments according to the invention may also be produced by replication of DNA or RNA, by transcription from DNA to form RNA fragments or reverse transcription from RNA fragments to form DNA fragments. Such transcription may be in a cell free system or may be effected in cells for instance by cloning.
  • Cell free systems include an appropriate replicase, transcriptase or reverse transcriptase, suitable nucleotide precursors and a r- cleic acid template of appropriate sequence, together with buffers and any necessary or desirable cofactors [see Maniatis] .
  • Cloning may be conducted by conventional techniques well known in the art of recombinant DNA technology [see Maniatis] .
  • the invention therefore provides a process for producing nucleic acid fragments as hereinbefore defined by linking nucleotides or oligonucleotides in an appropriate sequence and recovering the fragments from the reaction medium or cell debris.
  • the fragments are preferably cloned by inclusion in a suitable cloning vector containing appropriate restriction endonuclease recognition and cutting sites for excision of the cloned fragments from the vector.
  • suitable cloning systems such as transfected bacterial or yeast cells (e.g. Escherichia coli or Saccharomvces cerevisiae) .
  • suitable cloning vectors include plasmids, cosmids and viral genomic nucleic acids. Construction of the vectors and cloning thereof may be by conventional methods such as described in Maniatis.
  • the nucleic acid fragments of the invention may all be used as hybridisation probes and polymerase chain reaction primers for identifying DNA or RNA encoding at least a portion of scatter factor. Coding strands and double stranded fragments including a coding strand, (ie. fragments of the first class described above) may also be used in the expression of, or to construct sequences which will enable expression of, polypeptides and proteins of the invention including the expression of scatter factor.
  • Fragments according to the invention have a number of uses associated with the diagnosis and therapy of cancers and wound healing, for instance:
  • Fragments of the invention may be used as primers to initiate the polvmerase chain reaction (PCR) .
  • the use of the PCR to detect such cells is particularly important in seeking to establish whether metastasis is likely to occur. It is also useful in detecting allele loss or translocation events (whereby the whole or a segment of the scatter factor gene is deleted or moved to an inappropriate site in the genome leading to aberrant expression of scatter factor or that part of the scatter factor molecule encoded by the translocated segment) . Such allele loss or translocation events may be indicative of cancerous or pre-cancerous abnormalities.
  • the fragments of the present invention are preferably at least 17 bases in length. They are preferably used in conventional manner.
  • Fragments of the invention may be used as hybridization probes.
  • hybridization probes may be used for detecting nucleic acids of complementary sequence in samples, for instance for detecting tumour cells actively aberrantly expressing scatter factor, and in the detection of allele loss and translocation events as described under (i) above.
  • the fragments of the present invention are preferably at least 17 bases or base pairs in length.
  • the probes of the invention may be labelled with conventional detectable labels such as radionuclides, enzyme labels, fluorescent labels or other directly or indirectly detectable conventional labels.
  • the fragmerts may be bound to a solid support.
  • the labelling of probes and the binding of probes to solid supports are well-known technologies and may be achieved by methods known to those skilled in the art. Hybridization using these probes is conducted in conventional manner for instance as described by Maniatis.
  • Class one fragments of the invention may be included in expression vectors and thus direct the production of polypeptides Such polypeptides have a sequence corresponding to at least a portion of scatter factor and thus have diagnostic and therapeutic uses and may be used to generate therapeutically or diagnostically useful antibodies as discussed below.
  • class one fragments according to the present invention will be incorporated in functional form into suitable expression systems using expression vectors and appropriate hoot cells, for instance mammalian cells.
  • expression vectors include plasmids and viral genomic nucleic acids.
  • the fragments of the invention form the whole or a part of a coding sequence accompanied by any necessary or desirable regulatory and promoter sequences, transcriptional and translational initiation and termination signals, splicing and ligation sites and marker sequences in appropriate order, reading frame register and spacing and optionally further including restriction endonuclease recognition and cutting sites.
  • Coding sequences including fragments according to the invention may encode fusion proteins, for instance comprising a polypeptide encoded by the fragment of the invention linked to a carrier protein, such as keyhole limpet haemocyanin, albumen or thyroglobulin. Such fusion proteins are particularly useful when the polypeptide is to be used as an immunogen. In other fusion proteins the polypeptide is linked to other parts of scatter factor.
  • the vector is viral genomic DNA and the fragment of the invention is inserted in a functional gene expressed by virus - infected cells; an example of this is when the fragment is incorporated into the gene for the capsid protein of polio virus and the vector is polio virus genomic DNA (see, for instance Burke et al. , Nature (London) 332: 81-82 (1989)).
  • the vector will be selected according to the host cell to be used to express the polypeptides encoded by fragments of the invention and may be constructed by conventional recombinant DNA techniques (see, for instance, Maniatis)
  • the present invention further provides cloning and expression vectors as hereinbefore described containing fragments according to the invention and processes for their production by insertion of the fragments into the vector. Also encompassed within the invention are cells transformed or transfected with such cloning or expression vectors and processes for their production by transformation and transfection of the cells with the vector.
  • the invention also extends to processes for cloning fragments according to the invention in cells transformed or transfected with such cloning vectors by culturing the cells, excising the fragments of the invention from the cloned vectors and recovering the fragments.
  • the invention further extends to processes for expressing polypeptides encoded by class one fragments of the invention by culturing cells transformed or transfected with expression vectors as described above and recovering the polypeptides.
  • the construction of vectors, transformation or transfection of cells and culturing of cells and recovery of nucleic acid fragments or polypeptides may all be accomplished by conventional methods, such as described in Maniatis. Antibodies
  • polypeptides and proteins of the invention will be administered to a host according to a conventional immunisation schedule.
  • Immunisation schedules are well-known to those skilled in the art and generally comprise administration of several separate doses at intervals of from a few days to weeks or even months or years and may include, booster doses at intervals of several years.
  • the polypeptides and proteins of the invention are administered parenterally in solution or suspension in a suitable diluent or carrier and together with a suitable adjuvant.
  • Antibodies or antibody-producing cells are then recovered from the tissue, for instance the spleen or body fluids of the host.
  • Antibodies are preferably recovered from the blood or serum.
  • Antibody-producing cells are preferably recovered from the spleen or from peripheral blood samples and are then used to produce antibodies following immortalisation. Alternatively DNA from the antibody-producing cells is used in other cells to produce antibodies.
  • the present invention provides antibodies against a polypeptide or protein as hereinbefore defined.
  • Such antibodies may be obtained by conventional methods [Williams, Tibtech. 6 . :36, (1988) and are useful in diagnostic and therapeutic applications, such as passive immunisation.
  • antibody is intended to include polyclonal and monoclonal antibodies and fragments of antibodies bearing antigen binding sites such as the F(ab') 2 fragments as well as such antibodies or fragments thereof which have been modified chemically or genetically in order to vary the amino acid residue sequence of one or more polypeptide chains, to change the species specific and/or isotype specific regions and/or to combine polypeptide chains from different sources. Especially in therapeutic applications it may be appropriate to modify the antibody by grafting either the V regions or the CDR loops of the non-human antibody into the human framework or C region sequences, or in order to vary the isotype of the antibody (see EP-A-0,239,400) .
  • antibodies used herein is further intended to encompass antibody molecules or fragments thereof as defined above produced by recombinant DNA techniques as well as so-called “single domain antibodies” or “dAbs” such as are defined by Ward, E.S. et al. , Nature. 341:544-546 (1989) which are produced in recombinant microorganisms, such as Escherichia coli. harboring expressible DNA sequences derived from the DNA encoding the variable domain of an immunoglobulin heavy chain.
  • dAbs may be produced with higher affinities and obtained by screening a library of such randomly mutated DNA sequences and selecting those which enable expression of polypeptides capable of specifically binding the polypeptides or proteins of the invention or scatter factor.
  • Antibodies according to the present invention react specifically with scatter factor.
  • Such antibodies may be obtained by conventional methods by immunisation of a host and recovery from a tissue or body fluid thereof or by culturing an antibody-producing cell line as described below.
  • Antibodies according to the invention are useful in therapy and diagnosis of cancers particularly in inhibiting or assessing the likelihood of metastasis.
  • the antibodies may be used for other purposes including screening cell cultures for the polypeptide or protein expression product of class one nucleotide fragments of the invention, particularly the nascent expression products.
  • the antibodies may be administered conventionally to afford passive immunity in the recipient to mutant scatter factor expressed by cancer cells.
  • the antibodies are administered parenterally in the form of pharmaceutical formulations comprising a pharmaceutically acceptable carrier or diluent and optionally further comprising preservatives, antioxidants, suspending agents such as detergents and emulgents, buffers and isotonic agents. Dosages will be selected according to the age, weight or body area, sex and state of health of the patient and the size and severity of the tumour to be treated. Preferably the antibodies are administered at from 1 to 20 mg, for instance 2 to 10 mg and most preferably at about 5 mg.
  • the antibodies may be linked to or used in conjunction with a diagnostically effective ligand, such as a solid support or a label such as an enzyme label, radiolabel or fluorescent label or other directly or indirectly detectable label.
  • a diagnostically effective ligand such as a solid support or a label such as an enzyme label, radiolabel or fluorescent label or other directly or indirectly detectable label.
  • the diagnostically effective ligand may be linked to the antibody or used separately.
  • a label is targeted to cells expressing scatter factor by the antibody linked thereto or administered separately (simultaneously or sequentially in either order) therewith, the targeted label may be used in tumour detection, localisation and imaging.
  • the antibodies will generally be administered intravenously by injection or infusion, preferably as a pharmaceutical formulation comprising a pharmaceutically acceptable diluent or carrier and optional accessory ingredients as described above. Amounts to be administered in each case will be determined according to the efficacy and serum half-life of the antibody and the patient's tolerance of the agents.
  • the ligand may be a solid support or a label such as an enzyme label, chromophore, fluorophore or a radioisotope or other conventional directly or indirectly detectable label.
  • any therapeutically or diagnostically effective ligand not linked to the antibody When administered to a patient or used in a diagnostic test or assay procedure any therapeutically or diagnostically effective ligand not linked to the antibody must be capable of specifically binding with the antibody or must be linked to a moiety itself capable of specifically binding to the antibody.
  • the antibodies may also be used in conventional diagnostic tests and assay methods to detect cells expressing scatter factor, circulating scatter factor or degradation products thereof.
  • the antibodies may be linked to labels such as radionuclides, fluorescent labels and enzyme labels or to particles or solid supports. Such labelling is achieved by conventional methods well-known in the art.
  • the assays or tests may be conducted by any known method such as radio-immuno assay or enzyme-linked immunoadsorbant assay using any conventional sandwich technique or by competitive test or assay methods.
  • the present invention also provides an antibody as hereinbefore defined linked to a therapeutically or diagnostically effective ligand and processes for their production comprising linking a suitable ligand to the antibody optionally via a linking group.
  • the invention further provides a diagnostic test or assay process comprising contacting a sample suspected to contain a polypeptide or protein as hereinbefore defined or scatter factor with an antibody of the invention.
  • the antibody is incubated with the sample to permit binding of the antibody to the polypeptide, protein or scatter factor and the presence of bound or unbound antibody is then detected.
  • the antibody may be linked to a diagnostically effective ligand or such a ligand (provided that it is capable of specifically binding with the antibody or is provided with a moiety capable of specifically binding with the antibody) is used separately.
  • the invention therefore provides a process for producing an antibody according to the invention which comprises immunising a host animal with a polypeptide or protein as hereinbefore described.
  • the invention provides a process for producing an antibody according to the invention which comprises recovering the antibody from a body fluid of a host animal inoculated with a polypeptide or protein as hereinbefore defined.
  • Monoclonal antibodies are produced by culturing immortalised cells which secrete antibodies as hereinbefore defined.
  • Cells which secret such antibodies are obtained from host animals inoculated as above.
  • Immortalisation may be by any conventional technique, for instance by the use of Epstein-Barr virus or hybridization with an immortal cell line, such as a myeloma of the same or a different species to the host animal, to form a hybridoma.
  • the present invention therefore provides a cell capable of secreting an antibody as hereinbefore defined.
  • the invention further provides a process for producing such a cell comprising inoculating a host animal with a polypeptide or protein as hereinbefore defined and recovering antibody producing cells from the host animal.
  • the invention further provides an immortal cell line capable of secreting an antibody as hereinbefore defined or an immortal cell of such a cell line.
  • the invention further provides a process for producing an immortal cell or cell line capable of secreting antibody according to the present invention comprising recovering antibody-secreting cells from a host animal inoculated with a polypeptide or protein as hereinbefore defined and immortalising the anti-body secreting cells.
  • the process further comprises selecting cells capable of secreting antibodies as hereinbefore defined prior to an /or after immortalisation.
  • the invention further provides a process for producing a monoclonal antibody as hereinbefore described comprising culturing an immortalised cell as described above and recovering antibody from the culture medium and/or cell debris.
  • Conventional culture conditions may be employed for n vitro or in vivo (for instance in the peritoneum) growth of the cells.
  • Antibody recovery from body fluids (such as ascites) and culture media or cell debris is by conventional techniques, for instance, involving separation steps and/or affinity chromatography.
  • Antibodies according to the present invention may also be produced by expression of DNA and RNA encoding the antibodies which DNA or RNA has been recovered from antibody-secreting cells, such as cells obtained from the spleen or peripheral blood of inoculated host animals or immortalised cells as described above.
  • antibody-secreting cells such as cells obtained from the spleen or peripheral blood of inoculated host animals or immortalised cells as described above.
  • Such expression may be effected using conventional expression systems employing expression vectors such as cosmids, plasmids or viral genomic nucleic acids and transforming or transfecting appropriate host cells with such expression vectors then culturing the transformed or transfected cells and recovering antibody from the culture medium or cell debris.
  • expression vectors such as cosmids, plasmids or viral genomic nucleic acids and transforming or transfecting appropriate host cells with such expression vectors then culturing the transformed or transfected cells and recovering antibody from the culture medium or cell debris.
  • a polypeptide or protein as hereinbefore defined to a human or animal in need thereof.
  • the administration may be by any conventional route and dosage regime and the agent may be administered in the form of a pharmaceutical composition as hereinbefore described.
  • the invention further provides any one of the following agents:
  • polypeptide or protein as hereinbefore defined; for use in a method of treatment of the human or animal body or in a method of diagnosis practiced on the human or animal body.
  • the invention further provides the use of any one of the following agents: (a) a nucleic acid fragment as hereinbefore defined; (b) an expression vector containing a nucleic acid of (a) above;
  • an antibody as hereinbefore defined or (e) a cell capable of secreting an antibody of (d) above; or (f) a polypeptide or protein as hereinbefore defined in the production of a medicament for use in a method of treatment of the human or animal body or a method of diagnosis practiced on the human and animal body.
  • Residue 13 is unassigned. Residue in position 18 is probably Leu.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polypeptide ou protéine comportant au moins cinq résidus contigus d'aminoacide dans une séquence qui correspond à la formule (I), VVNGIPTQTTVGX1MVSLX2YY dans laquelle le code à une lettre globalement reconnu sert à représenter les résidus d'aminoacide, X1 est un résidu d'aminoacide-L se trouvant dans la nature, et X2 est un résidu d'aminoacide, de préférence un résidu de leucine-L (L).
PCT/GB1991/000245 1990-02-16 1991-02-15 Facteur proteique Ceased WO1991012272A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9003621.1 1990-02-16
GB909003621A GB9003621D0 (en) 1990-02-16 1990-02-16 Protein factor

Publications (1)

Publication Number Publication Date
WO1991012272A1 true WO1991012272A1 (fr) 1991-08-22

Family

ID=10671172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000245 Ceased WO1991012272A1 (fr) 1990-02-16 1991-02-15 Facteur proteique

Country Status (2)

Country Link
GB (1) GB9003621D0 (fr)
WO (1) WO1991012272A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492614A3 (en) * 1990-12-28 1993-02-10 Toshikazu Nakamura Epitheliocyte growth accelerator
EP0805203A1 (fr) * 1992-09-18 1997-11-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Utilisation d'une substance empêchant une liaison de HGS/SF avec Met
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
WO2001034650A1 (fr) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Combinaison d'anticorps monoclonaux hgf-sf
EP1734995A1 (fr) 2004-04-15 2006-12-27 Galaxy Biotech, LLC Anticorps monoclonaux du facteur de croissance des hepatocytes
WO2008020119A1 (fr) * 2006-08-16 2008-02-21 Licentia Ltd. Fibroblastes activés pour traiter les dommages de tissus et/ou d'organes
US8609090B2 (en) 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412557A1 (fr) * 1989-08-11 1991-02-13 Mitsubishi Chemical Corporation Facteur de croissance de cellules hépatiques parenchymateuses, son gène, procédé de production de ce facteur et de transformants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412557A1 (fr) * 1989-08-11 1991-02-13 Mitsubishi Chemical Corporation Facteur de croissance de cellules hépatiques parenchymateuses, son gène, procédé de production de ce facteur et de transformants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, volume 163, no. 2, 15 September 1989, Academic Press, Inc. K. Miyazawa et al.: "Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor", pages 967-973 *
Biochemical and Biophysical Research Communications, volume 163, no. 3, 29 September 1989, Academic Press, Inc. R. Zarnegar et al.: "NH2-terminal amino acid sequence of rabbit hepatopoietin A, a heparin-binding polypeptide growth factor for hepatocytes, pages 1370-1376 *
Biochemical and Biophysical Research Communications, volume 172, no. 1, 15 October 1990, Academic Press, Inc., T. Seki et al.: "Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte", pages 321-327 *
Proc. Natl. Acad. Sci., volume 86, August 1989, Cell Biology, E. Gherardi et al.: "Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement", pages 5844-5848 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
US5342831A (en) * 1990-12-28 1994-08-30 Toyo Boseki Kabushiki Kaisha Epitheliocyte growth accelerator
EP0492614A3 (en) * 1990-12-28 1993-02-10 Toshikazu Nakamura Epitheliocyte growth accelerator
EP0805203A1 (fr) * 1992-09-18 1997-11-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Utilisation d'une substance empêchant une liaison de HGS/SF avec Met
US5965523A (en) * 1993-10-18 1999-10-12 North Shore University Hospital Research Corporation Method for enhancing transplanted tissue using scatter factor
US5919759A (en) * 1993-10-18 1999-07-06 North Shore University Hospital Research Corporation Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5997868A (en) * 1993-10-18 1999-12-07 North Shore University Hospital Research Corporation Inhibition of scatter factor for blocking angiogenesis
WO2001034650A1 (fr) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Combinaison d'anticorps monoclonaux hgf-sf
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
US8609090B2 (en) 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor
EP1734995A1 (fr) 2004-04-15 2006-12-27 Galaxy Biotech, LLC Anticorps monoclonaux du facteur de croissance des hepatocytes
WO2008020119A1 (fr) * 2006-08-16 2008-02-21 Licentia Ltd. Fibroblastes activés pour traiter les dommages de tissus et/ou d'organes

Also Published As

Publication number Publication date
GB9003621D0 (en) 1990-04-11

Similar Documents

Publication Publication Date Title
KR100227303B1 (ko) 인체 t 임파구 수용체의 베타 사슬의 가변성 영역을 코딩하는 뉴클레오티드 서열, 대응하는 펩티드 세그먼트 및 진단 및 치료 용도
Kumar et al. Cloned cytochrome P-450 cDNA. Nucleotide sequence and homology to multiple phenobarbital-induced mRNA species.
JP2882775B2 (ja) ヒトーグリア由来神経突起因子
US5326857A (en) ABO genotyping
JPH09512161A (ja) ヒトｔ（２；５）リンパ腫に存在する特異的融合核酸及びタンパク質、それらの検出方法及び用途
KR860001515B1 (ko) 사람의 전(前) 성장(pre-growth)호르몬의 아미노산 배열을 함유하는 단백질의 제조방법
EP0991759A1 (fr) Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
CA2309783A1 (fr) Facteur de croissance des fibroblastes 19
JPH02295487A (ja) キメラモノクローナル抗体の産生のための発現系
Wolf et al. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species
Devlin et al. Secretion of a soluble class I molecule encoded by the Q10 gene of the C57BL/10 mouse.
US4918162A (en) Assays and antibodies for N-MYC proteins
JPH05509234A (ja) ヒトＴリンパ球レセプターのα鎖の可変領域をコードするヌクレオチド配列対応するペプチドセグメント並びに診断及び治療への利用
EP0766736A1 (fr) Anticorps monoclonaux humains specifiques vis-a-vis d'antigenes de surface de gliomes, independants du cycle cellulaire
Kay et al. Potential for two isoforms of the A1 ribonucleoprotein in Xenopus laevis.
WO1991012272A1 (fr) Facteur proteique
JPH05502789A (ja) ムチンヌクレオチド
CA2195090A1 (fr) Operon et genes de structure de piline de lkp de haemophilus influenzae inclassables
US6329198B1 (en) Production and use of human nm23 protein and antibodies therefor
Adams et al. Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for. mu.,. alpha.,. gamma. 1,. gamma. 2a, and. gamma. 3 chains
JPH05500506A (ja) Ｇｔｐアーゼ活性化タンパク質（ｇａｐ）からのペプチドおよびその診断および治療学的使用
IE980956A1 (en) Nucleic Acid Encoding a Nervous Tissue Sodium Channel
AU7480387A (en) Assays and antibodies for n-myc proteins
JP3065628B2 (ja) ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法
CA2440679A1 (fr) Enzymes et utilisations les concernant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE